Royalty Pharma PLC - ESG Rating & Company Profile powered by AI
This assessment of Royalty Pharma PLC incorporates intelligence from across the web as well as from public documents by Royalty Pharma PLC. Alternative corporations in the rating peer group for Royalty Pharma PLC are displayed. The webpage contains a questions and answers table on Royalty Pharma PLC.
Royalty Pharma PLC in the Pharmaceuticals industry gained a UN SDG ESG Transparency Score of 0.0; made up of an environmental score of 0.0, social score of 0.0 and governance score of 0.0.
0.0
Low ImpactEnvironmental
Social
Governance
Peer Group Comparison
| Rank | Company | SDG Transparency Score ⓘ | Performance |
|---|---|---|---|
| 1 | Caladrius Biosciences Inc | 8.0 | High |
| 1 | Can Fite Biopharma Ltd | 8.0 | High |
| ... | ... | ... | |
| 1967 | Hospira Inc | 0.3 | Low |
| 1967 | PRA Health Sciences Inc | 0.3 | Low |
| 1970 | Royalty Pharma PLC | 0.0 | Low |
| 1970 | CSPC Innovation Pharmaceutical Co Ltd | 0.0 | Low |
| 1970 | CTC Bio Inc | 0.0 | Low |
| 1970 | Zyden Gentec Ltd | 0.0 | Low |
| 1970 | iNtRON Biotechnology Inc | 0.0 | Low |
| ... | ... | ... |
Frequently Asked Questions
Does Royalty Pharma PLC have an accelerator or VC vehicle to help deliver innovation?
Sign up for free to unlockDoes Royalty Pharma PLC disclose current and historical energy intensity?
Sign up for free to unlockDoes Royalty Pharma PLC report the average age of the workforce?
Sign up for free to unlockDoes Royalty Pharma PLC reference operational or capital allocation in relation to climate change?
Sign up for free to unlockDoes Royalty Pharma PLC disclose its ethnicity pay gap?
Sign up for free to unlockDoes Royalty Pharma PLC disclose cybersecurity risks?
Sign up for free to unlockDoes Royalty Pharma PLC offer flexible work?
Sign up for free to unlockDoes Royalty Pharma PLC have a long term incentive (LTI) executive compensation plan based on a measure of return on capital?
Sign up for free to unlockDoes Royalty Pharma PLC disclose the number of employees in R&D functions?
Sign up for free to unlockDoes Royalty Pharma PLC conduct supply chain audits?
Sign up for free to unlockDoes Royalty Pharma PLC disclose incidents of non-compliance in relation to the health and safety impacts of products and services?
Sign up for free to unlockIs there a statment that there is no plan to expand their cement production? (for example: 'We have no current plans to add additional cement making capacity')
Sign up for free to unlockDoes Royalty Pharma PLC conduct 360 degree staff reviews?
Sign up for free to unlockDoes Royalty Pharma PLC disclose the individual responsible for D&I?
Sign up for free to unlockDoes Royalty Pharma PLC disclose current and historical air emissions?
Sign up for free to unlockIs there a statment that there is no plan to expand their coal usage? (for example: 'We have no current plans to add additional coal powered electricity generation')
Sign up for free to unlockIs executive remuneration linked to climate performance?
Sign up for free to unlockDoes the Board describe its role in the oversight of climate-related risks and opportunities?
Sign up for free to unlockDoes Royalty Pharma PLC disclose current and / or historical scope 2 emissions?
Sign up for free to unlockDoes Royalty Pharma PLC disclose water use targets?
Sign up for free to unlockDoes Royalty Pharma PLC have careers partnerships with academic institutions?
Sign up for free to unlockDid Royalty Pharma PLC have a product recall in the last two years?
Sign up for free to unlockDoes Royalty Pharma PLC disclose incidents of discrimination?
Sign up for free to unlockDoes Royalty Pharma PLC allow for Work Councils/Collective Agreements to be formed?
Sign up for free to unlockHas Royalty Pharma PLC issued a profit warning in the past 24 months?
Sign up for free to unlockDoes Royalty Pharma PLC disclose parental leave metrics?
Sign up for free to unlockDoes Royalty Pharma PLC disclose climate scenario or pathway analysis?
Sign up for free to unlockDoes Royalty Pharma PLC disclose current and / or historical scope 1 emissions?
Sign up for free to unlockAre Operating Expesnses linked to emissions reduction?
Sign up for free to unlockDoes Royalty Pharma PLC disclose the pay ratio of women to men?
Sign up for free to unlockDoes Royalty Pharma PLC support suppliers with sustainability related research and development?
Sign up for free to unlockDoes Royalty Pharma PLC disclose the number of operations that have been subject to human rights reviews or human rights impact assessments?
Sign up for free to unlockDoes Royalty Pharma PLC reflect climate-related risks in its financial statements?
Sign up for free to unlockIs there a statment that there is no plan to expand their carbon intensite energy assets? (for example: 'We have no current plans to carry out further drilling for oil,')
Sign up for free to unlockIs Royalty Pharma PLC involved in embryonic stem cell research?
Sign up for free to unlockDoes Royalty Pharma PLC disclose GHG and Air Emissions intensity?
Sign up for free to unlockDoes Royalty Pharma PLC disclose its waste policy?
Sign up for free to unlockDoes Royalty Pharma PLC report according to TCFD requirements?
Sign up for free to unlockDoes Royalty Pharma PLC disclose its policies for bribery, corruption, whistle-blower, conflict of interest?
Sign up for free to unlockDoes Royalty Pharma PLC disclose energy use targets?
Sign up for free to unlockDoes Royalty Pharma PLC disclose its Renewable Energy targets?
Subscription requiredAre emissions metrics verified by STBi?
Subscription requiredDoes Royalty Pharma PLC have a policy relating to cyber security?
Sign up for free to unlockHave a different question?
Potential Risks for Royalty Pharma PLC
These potential risks are based on the size, segment and geographies of the company.
Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States. It is also involved in the identification, evaluation, and acquisition of royalties on various biopharmaceutical therapies. In addition, the company collaborates with innovators from academic institutions, research hospitals and not-for-profits, small and mid-cap biotechnology companies, and pharmaceutical companies. Its portfolio consists of royalties on approximately 35 marketed therapies and 10 development-stage product candidates that address various therapeutic areas, such as rare disease, cancer, neurology, infectious disease, hematology, and diabetes. The company was founded in 1996 and is based in New York, New York.